Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case series detailed three postmenopausal women with ovarian steroid cell tumors, highlighting that such tumors may present asymptomatically or with virilization, and found surgery effectively normalized androgen levels, with distinctive imaging features aiding diagnosis.

This study assessed clinical patterns of skin and mucosal symptoms in postmenopausal women, finding that a significant number experienced conditions like atrophic vaginitis, oral complaints, and hair loss, often without realizing their menopausal link.

In this case study, laparoscopic bilateral salpingo-oophorectomy was associated with reduced androgen levels and partial reversal of male-pattern hair loss in a postmenopausal woman with ovarian hyperandrogenism.

Over 40% of postmenopausal women experience hair loss, with treatments aiming to stop further loss and possibly thicken hair.

In this study, finasteride 1 mg daily did not improve hair loss in normoandrogenic postmenopausal women and had a similar adverse event profile to placebo within the first year.

This study concludes that hormone therapy can significantly improve skin hydration, elasticity, thickness, and reduce wrinkles by modulating various skin cells through estrogen receptors.

This study observed that the size of vaginal prolapse in patients was significantly related to both the preoperative vaginal length and the length of vaginal excision during the Michigan four-wall sacrospinous suspension procedure.

There is no abstract available for this article on the effects of percutaneous oestradiol implants on the skeletons of postmenopausal women, and thus no new findings are reported.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

The document did not provide enough information to summarize the causes of hair loss in pre- and postmenopausal women.

This case report highlights the adverse effects of unmonitored bioidentical hormone replacement therapy, emphasizing the need for patient education about its safety and efficacy compared to FDA-regulated hormones.

A postmenopausal woman's masculine symptoms improved after surgery for a hormone-producing ovarian tumor.

Among postmenopausal women, this case study observed that a rare ovarian tumor called thecoma, found via MRI, was associated with high testosterone levels and symptoms of mild virilization such as hirsutism, indicating surgery as the primary treatment.

This case report details a 73-year-old woman with significant hirsutism and hair loss linked to a rare ovarian Leydig cell tumor, which was resolved by bilateral salpingo-oophorectomy, normalizing her testosterone levels and addressing her symptoms.

This study investigated dermatological conditions among 223 Indian postmenopausal women, reporting that 83.4% had skin disorders, 29.1% had genital symptoms, 10.3% had oral issues, 33.6% experienced hair disorders, and 26% faced nail problems.

This case report highlights the diagnostic challenge of identifying androgen-secreting ovarian Leydig cell tumors in postmenopausal women when imaging fails to reveal masses, emphasizing the usefulness of ovarian vein sampling for localization.

A postmenopausal woman's virilization was caused by a rare ovarian tumor that was hard to detect but was successfully treated with surgery.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

This review presents substantial evidence supporting testosterone use for hypoactive sexual desire disorder in postmenopausal women, but notes safety concerns with off-label prescribing due to lack of approved formulations.

This retrospective study found that serum hormone levels and MRI detection of ovarian nodules contributed to distinguishing virilizing ovarian tumors from ovarian stromal hyperthecosis in postmenopausal women, though histopathology remains crucial for diagnosis.

This review discusses ovarian hyperthecosis as a rare cause of androgenetic alopecia in postmenopausal women and reports no new results; the authors highlight the need to explore its relationship to alopecia further.

This study found that cryptotanshinone improved bone mass, inhibited osteoclast differentiation, and protected against kidney damage in ovariectomized rats, suggesting potential benefits for clinical use.

This review discusses hormonal changes during menopause, emphasizing the relative androgen excess and the role of insulin resistance, and reports no new clinical findings.

This study found that postmenopausal women with a history of hirsutism and/or oligo-amenorrhea have a higher prevalence of several comorbidities, including heart and respiratory diseases, than those without these reproductive history markers.

This case study reported a postmenopausal woman with a testosterone-secreting ovarian tumor that was not detected through standard clinical or radiological examination but was found via biopsy.

The painting of an 18th-century Sicilian baroness shows she had hair loss, possibly due to ovarian issues, insulin resistance, or a specific type of tumor.

This case report describes a 64-year-old postmenopausal woman with hirsutism due to a rare case of bilateral diffuse ovarian Leydig cell hyperplasia, leading to normalized testosterone levels and improved glycaemic control following surgery.

Hair loss in postmenopausal women due to ovarian hyperthecosis is rare, but removing the ovaries can significantly improve the condition.

This study found no significant differences in hormone levels between postmenopausal women with androgenetic alopecia and healthy controls, suggesting potential alternative causes for the condition.

This case report highlights that in postmenopausal women with severe hyperandrogenism, thorough adrenal and pelvic evaluations, hormonal profiling, and permanent pathology are essential for accurate diagnosis and management of androgen-secreting tumors, such as AGCTs, to prevent misdiagnosis and ensure effective treatment.